НОВЫЙ ПРОТИВОТУБЕРКУЛЕЗНЫЙ ПРЕПАРАТ ПРЕТОМАНИД ДЛЯ ЛЕЧЕНИЯ ЛЕКАРСТВЕННО-УСТОЙЧИВОГО ТУБЕРКУЛЕЗА (ОБЗОР)
https://doi.org/10.24412/2790-1289-2023-1-65-72
Аннотация
В обзоре использовано 61 источников литературы, посвященных новому противотуберкулезному препарату PA-824-претоманиду, который проявляет антимикробную активность против штаммов микобактерии туберкулеза с лекарственной устойчивостью. Согласно изученным данным, комбинации претоманида с другими химиопрепаратами высокоэффективны и перспективны при проведении лечения пациентов с лекарственно-устойчивым туберкулезом.
Об авторе
Г. А. Смаилова
НУО «Казахстанско-Российский медицинский университет»
Казахстан
Казахстан
Смаилова Гульнара Аскаровна, доктор медицинских наук, профессор
Алматы
Список литературы
1. Ваксман Зельман Абрахам. Википедия. [Электронный ресурс. URL: https: //ru.wikipedia.org/wiki/%D0%92%D0%B0%D0%BA%D1%81%D0%BC%D0%B0%D0%BD,_%D0%97%D0%B5%D0%BB%D1%8C%D0%BC%D0%B0%D0%BD_%D0%90%D0%B1%D1%80%D0%B0%D1%85%D0%B0%D0%BC. [Vaksman Zel'man Abraham. Vikipedija.[Jelektronnyj resurs. URL: https://ru.wikipedia.org/wiki/%D0%92%D0%B0%D0%BA%D1%81%D0%BC%D0%B0%D0%BD,_%D0%97%D0%B5%D0%BB%D1%8C%D0%BC%D0%B0%D0%BD_%D0%90%D0%B1%D1%80%D0%B0%D1%85%D0%B0%D0%BC.
2. Кукурика А. В. Претоманид: клинические испытания и перспективы применения в схемах лечения туберкулеза с множественной и широкой лекарственной устойчивостью // Туберкулёз и болезни лёгких. – 2021. – Т. 99, № 6. – С. 54-60. http://doi.org/10.21292/2075-1230-2021-99-6-54-60.
3. Луговкина Т.К., Скорняков С.Н., Кильдюшева Е.И., Егоров Е.А. Современные подходы к поиску активных препаратов, схем и режимов химиотерапии туберкулеза // Туберкулёз и болезни лёгких. – 2020. – Т. 98, № 6. – С. 60-69. http://doi.org/10.21292/2075-1230-2020-98-6-60-69.
4. Мишин В.Ю. Современные режимы химиотерапии туберкулеза легких, вызванного лекарственно - чувствительными и лекарственно-резистентными микобактериями. РМЖ. 2003; 21:1163.
5. Наумов А.Г., Павлунин А.В. Стратегия борьбы с лекарственно-устойчивым туберкулезом: Перспективные режимы химиотерапии (обзор литературы) // Вестник новых медицинских технологий. Электронное издание – 2019 – N 5.-С.57-65.
6. Промежуточный анализ endTB - июль, 2018.
7. Рабухин А.Е. Химиотерапия больных туберкулезом легких. – М. – 1970. – 400 с.
8. Хоменко А.Г. Химиотерапия туберкулеза легких. – М. – 1980. – 279 с.
9. Хоменко А.Г. Туберкулез. // Руководство для врачей. – М. – 1996. – 493 с.
10. Хоменко А.Г. Химиотерапия туберкулеза – история и современность. // Пробл. туб. – 1996. – № 3. – С. 2 – 6.
11. Чуканов В.И. Основные принципы лечения больных туберкулезом легких. // Русский медицинский журнал. – 1998. – Том 6. – № 17. – С. 1138 – 1142.
12. A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource. URL: https:// clinicaltrials. gov/ct2/show/NCT02333799?term=NiX+TB& draw=2&rank=1 (accessed: 03.11.2020).
13. Ahmad Z., Peloquin C. A., Singh R. P., Derendorf H., Tyagi S., Ginsberg A., Grosset J. H., Nuermberger E. L. PA- 824 exhibits time-dependent activity in a murine model of tuberculosis // Antimicrob. Agents Chemother. ‒ 2011. ‒ Vol. 55. ‒ P. 239-245.
14. Berry C., du Cros P., Fielding K., Gajewski S., Kazounis E. e.a. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis // Trials. 2022 June 13; Volume 23 (Issue 1); 484; DOI: 10.1186/s13063-022-06331-8.
15. Bigelow K.M., Tasneen R., Chang Y.S., Dooley K.E., Nuermberger E.L. Preserved efficacy and reduced toxicity with intermittent Linezolid dosing in combination with Bedaquiline and Pretomanid in a murine tuberculosis model // Antimicrob. Agents Chemother. ‒ 2020. ‒ Vol. 64, № 10. ‒ P. 1178-1120.
16. Clinical Trials.gov. A Phase 3 study assessing the safety and efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects with drug resistant pulmonary tuberculosis. Bethesda (MD): National Library of Medicine (US); 2000.
17. Conradie F., Diacon A. H., Everitt D., Mendel C., Van Niekerk C., Howell P., Comins K., Spigelman M. The NIXTB trial of Pretomanid, Bedaquiline and Linezolid to treat XDR-TB. In Conference on retroviruses and opportunistic infections (CROI), 2017. ‒ P. 13-16.
18. Conradie F., Diacon A. H., Ngubane N., Howell P., Everitt D., Crook A. M., Mendel C. M., Egizi E., Moreira J., Timm J., McHugh T. D., Wills G. H., Bateson A., Hunt R., Van Niekerk C., Li M., Olugbosi M., Spigelman M. Treatment of highly drug-resistant pulmonary tuberculosis // New Engl. J. Med. ‒ 2020. ‒ Vol. 382, № 10. ‒ P. 892-902.
19. Dawson R., Diacon A. H., Everitt D., Christo van Niekerk, Donald P. R., Burger D. A., Schall R., Spigelman M., Conradie A., Eisenach K., Venter A., Ive P., Page-Shipp L., Variava E., Reither K., Ntinginya N. E., Pym A., Groote-Bidlingmaier F., Mendel C. M. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis // Lancet. ‒ 2015. ‒ Vol. 385. ‒ P. 1738-1747.
20. Dawson R., Harris K., Conradie A., Burger D., Murray S., Mendel C. et al. Efficacy of Bedaquiline, Pretomanid, Moxifloxacin & PZA (BPAMZ) Against DS- & MDR-TB. Conference on Retroviruses and Opportunistic Infections; Seattle, Washington: 2017.
21. De Miranda Silva C., Hajihosseini A., Myrick J., Nole J., Louie A., Schmidt S., Drusano G. L. Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an IN VITRO assay // Antimicrob. Agents. Chemother. ‒ 2018. ‒ Vol. 63, №1. ‒ P. 1695-1618.
22. De Miranda Silva C., Hajihosseini A., Myrick J., Nole J., Louie A., Schmidt S., Drusano G. L. Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay // Antimicrob. Agents. Chemother. ‒ 2018. ‒ Vol. 63, №1. ‒ P. 1695 - 1618.
23. Diacon A.H., Dawson R., Hanekom M., Narunsky K., Maritz S. J., Venter A., Donald P. R., van Niekerk C., Whitney K., Rouse D. J., et al. Early bactericidal activity and pharmacokinetics of PA-824 in smearpositive tuberculosis patients // Antimicrob. Agents. Chemother. ‒ 2010. ‒ Vol. 54. ‒ P. 3402-3407.
24. Dooley K. E., Luetkemeyer A. F., Park J., Allen R., Cramer Y., Murray S., Sutherland D., Aweeka F., Koletar S. L., Marzan F., Bao J., Savic J., Haas D. W. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin // Antimicrob. Agents. Chemother. ‒ 2014. ‒ Vol. 58, № 9. ‒ P. 5245-5252.
25. Dooley K.E., Rosenkranz S.L., Conradie F.., Moran L, Hafner R., von Groote-Bidlingmaier F., Lama J.R., Shenje J., De Los Rios J., Comins K., Morganroth J., Diacon AH, Cramer YS, Donahue K, Maartens G; AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team.QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomized, controlled trial// Lancet Infect Dis. 2021 Jul; 21 (7):975-983. doi: 10.1016/S1473-3099(20)30770-2. Epub 2021 Feb 12.PMID: 33587897.
26. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs | FDA [Electronic resource. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs (accessed: 03.11.2020).
27. Franke M.F., Khan P., Hewison C., Khan U., Huerga H., Seung K.J., Rich M., Zarli K., Samieva N., Oyewusi L., Nair P., Mudassar M., Melikyan N., Lenggogeni P., Lecca L., Kumsa A., Khan M., Islam S., Hussein K., Docteur W., Chumburidze N., Berikova E., Atshemyan H., Atwood S., Alam M., Ahmed S., Bastard M., Mitnick C.D. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study//Am J. Respir Crit Care Med. 2021 Jan 1; 203(1):111-119. doi: 10.1164/rccm.202001-0135OC.PMID:32706644.
28. Ginsberg A.M., Laurenzi M.W., Rouse D.J., Whitney K.D., Spigelman M.K. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects (англ.) // Antimicrob. Agents Chemother. (англ.) рус.:journal. — 2009. — September (vol. 53, no. 9). — P. 3720 — 3725. — doi:10.1128/AAC.00106-09. — PMID 19528280.
29. Khan U., Huerga H., Khan A.J., Mitnick C.D., Hevison K., Varaine F., Bastard M., Franke M.F., Atwood S., Khan P.Y., Seung K.J. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens// BMC Infect Dis. 2019 Aug 20; 19 (1):733. doi: 10.1186/s12879-019-4378-4.
30. Lenaerts A.J. et al. Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models // Antimicrob. Agents Chemother. — 2005. — Т. 49, № 6. — С. 2294 — 2301. — doi:10.1128/AAC.49.6.2294-2301.2005.
31. Lyons M. A. Modeling and simulation of Pretomanid pharmacodynamics in pulmonary tuberculosis patients // Antimicrob. Agents. Chemother. ‒ 2019. ‒ Vol. 63, № 12. ‒ P. 732-719.
32. Manjunatha U., Boshoff IM Helena, Barry C.E. The mechanism of action of PA-824 (неопр.) // Commun Integr Biol. — 2009. — May-Jun (т. 2, № 3). — С. 215 — 218.
33. Millard J., Pertinez H., Bonnett L. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation // The Journal of Antimicrobial Chemotherapy. 2018. Vol. 73, № 7. P. 1755 – 1762.
34. Nuermberger E., Rosenthal I., Tyagi S., Williams K. N., Almeida D., Peloquin C. A., Bishai W. R., Grosset J. H. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis // Antimicrob. Agents. Chemother. ‒ 2006. ‒ Vol. 50, № 8. ‒ Р. 2621-2625.
35. Nagarajan K., Shankar R.G., Rajappa S., Shenoy S.J., Costa-Pereira R. Nitroimidazoles. XXI. 2, 3 - Dihydro-6-nitroimidazo [2, 1-b oxazoles with antitubercular activity // Eur. J. Med. Chem. ‒ 1989. ‒ Vol. 24. ‒ Р. 631-633.
36. Nyang'wa BTBerry CKazounis EMotta IParpieva Net al. A 24-week, all-oral regimen for rifampin - resistant tuberculosis // N Engl J. Med. 2022 December 22; Volume 387; 2331 - 2343.; DOI: 10.1056/NEJMoa2117166.
37. Policy implementation package for new TB drug introduction. – WHO, Geneva, 2014.
38. PRETOMANID – инструкция к применению. https://pillintrip.com/medicine/pretomanid.
39. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis - WHO, Geneva, Мay, 2022 https://www.tbonline.info/posts/2022/5/2/key-changes-treatment-drug-resistant-tb/.
40. Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB, XDR-TB, Pre- XDRTB or Non-responsive/Intolerant MDR-TB (ZeNix) ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource. URL: https://clinicaltrials.gov/ct2/show/NCT03086486?term=Ze-Nix&draw=2&rank=1 (accessed: 03.11.2020).
41. Seung K.J., Khan P., Franke M.F., Ahmed S., Aiychiev S., Alan M., Putri F.A., Bastard M., Docteur W., Gottlieb G., Hevison K., Islam S., Khachatrian N., Kotrikadze T., Khan U., Kusmsa A., Lessa L., Tassew Y.M., Melikyan N., Naing Y.Y., Oyewusi L., Rich M., Wanjala S., Yedilbayev A., Huerga H., Mitnick C.D. Culture Conversion at 6 Months in Patients Receiving Delamanid - containing Regimens for the Treatment of Multidrug-resistant Tuberculosis// Clin Infect Dis. 2020 Jul 11;71(2):415-418. doi: 10.1093/cid/ciz1084.
42. Showalter H.D. Recent Progress in the Discovery and Development of 2 - Nitroimidazooxazines and 6 - Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases // Molecules. ‒ 2020. ‒ Vol. 25, № 18. ‒ Р. 4137.
43. Singh R., Manjunatha U., Boshoff H. I. PA - 824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release // Science. ‒ 2008. ‒ Vol. 322. ‒ Р. 1392 - 1395.
44. Silva D.R., Dalcolmo M., Tiberi S. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis // Jornal Brasileiro de Pneumologia. 2018. Vol. 44, № 2. P. 153 – 160.
45. Stover C.K., Warrener P., VanDevanter D.R., et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis (англ.) // Nature: journal. — 2000. — Vol. 405, no. 6789. — P. 962 — 966. — doi:10.1038/35016103. — PMID 10879539.
46. Sweeney S., Berry C., Kazounis E., Motta I., Vassall A. et al. Cost - effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis// PLOS Glob Public Health. 2022 December 7; Volume 2 (Issue 12); e0001337.; DOI:10.1371/journal.pgph.0001337.
47. Tasneen R., Tyagi S., Williams K., Grosset J., Nuermberger E. Enhanced bactericidal activity of rifampin and/ or pyrazinamide when combined with PA-824 in a murine model of tuberculosis // Antimicrob. Agents. Chemother. ‒ 2008. ‒ Vol. 52, № 10. ‒ Р. 3664-3668.
48. Tasneen R., Williams K., Amoabeng O., Minkowski A., Mdluli K. E., Upton A. M., Nuermberger E. L. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis// Antimicrob. Agents. Chemother. ‒ 2015. ‒ Vol. 59. ‒ Р. 129-135.
49. TB Alliance. Pretomanid. Sponsor briefing document antimicrobial drugs advisory committee. 2019.
50. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis.- WHO, Geneva, 2013.
51. The use of delamanid the treatment of multidrug-resistant tuberculosis.-WHO, Geneva, 2014.
52. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance - WHO, Geneva, 2016.
53. Tiberi S., Munoz-Torrico M., Duarte R. New drugs and perspectives for new anti-tuberculosis regi- mens // Pulmonology. 2018. Vol. 24, № 2. P. 86 – 98.
54. Thompson A. M., Bonnet M., Lee H. H., Franzblau S. G., Wan B., Wong G. S., Cooper C. B., Denny W. A. Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS Med Chem Lett, 2017. ‒ Vol. 8, № 12. ‒ Р. 1275-1280.
55. Tyagi S., Nuermberger E., Yoshimatsu T., Williams K., Rosenthal I., Lounis N., Bishai W., Grosset J. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis // Antimicrob. Agents. Chemother. ‒ 2005. ‒ Vol. 49, № 6. ‒ Р. 2289-2293.
56. Tweed G., Wills H., Crook A. M., Amukoye E., Balanag V., Ban A. Y.L., Bateson A. L.C., Betteridge M. C., Brumskine W., Caoili J., Chaisson R. E., Cevik M., Conradie F., Dawson R., del Parigi A., Diacon A., Everitt D. E., Fabiane S.M., Hunt R., Ismail A. I., Lalloo U., Lombard L., Louw C., Malahleha M., McHugh T. D., Mendel C. M., Mhimbira F., Moodliar R. N., Nduba V., Nunn A. J., Sabi I., Sebe M. A., Selepe R. A. P., Staples S., Swindells S., van Niekerk C. H., Variava E., Spigelman M., Gillespie S. H. A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB C. D. // INT J. TUBERC LUNG DIS 25 (4): 305–314 Q 2021 The Union http://dx.doi.org/10.5588/ijtld.20.0513.
57. Wallis R.S., Maeurer M., Mwaba P. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers // The Lancet. Infectious Diseases. 2016. Vol. 16, № 4.
58. WHO treatment guidelines for drug resistant tuberculosis: 2016 update -WHO, Geneva, 2016.
59. WHO treatment guidelines for multidrug - and rifampicin-resistant tuberculosis, 2018 update. - WHO, Geneva, 2018.
60. WHO consolidated guidelines on tuberculosis, module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
61. Xu J., Li S. Y., Almeida D. V., Tasneen R., Barnes-Boyle K., Converse P. J., Upton A. M., Mdluli K., Fotouhi N., Nuermberger E. L. Contribution of pretomanid to novel regimens containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in murine models of tuberculosis // Antimicrob. Agents. Chemother. ‒ 2019. ‒ Vol. 63, № 5. ‒ P. 19-21.
Рецензия
Для цитирования:
Смаилова Г.А. НОВЫЙ ПРОТИВОТУБЕРКУЛЕЗНЫЙ ПРЕПАРАТ ПРЕТОМАНИД ДЛЯ ЛЕЧЕНИЯ ЛЕКАРСТВЕННО-УСТОЙЧИВОГО ТУБЕРКУЛЕЗА (ОБЗОР). Актуальные проблемы теоретической и клинической медицины. 2023;(1):65-72. https://doi.org/10.24412/2790-1289-2023-1-65-72
For citation:
Smailova G. A NEW ANTI-TUBERCULOSIS DRUG PRETOMANID FOR THE TREATMENT OF DRUG-RESISTANT TB (REVIEW). Actual Problems of Theoretical and Clinical Medicine. 2023;(1):65-72. (In Russ.) https://doi.org/10.24412/2790-1289-2023-1-65-72
Просмотров:
441
